SANOFICONR.NS Sanofi Consumer HC (NSE) high volume 27 Feb 2026: +14.61% 4,644.77
SANOFICONR.NS stock led intraday activity on 27 Feb 2026 after a sharp volume surge and a 14.61% price jump to INR 4,595.00. Volume reached 167,833 versus an average of 3,684, giving a relative volume of 310.80. Traders reacted to the sudden flow, pushing the stock from a previous close of INR 4,009.20 to a day high of INR 4,786.00. This note breaks down the intraday volume spike, valuation context, technical read, Meyka AI grade, and practical trading levels for the NSE-listed Sanofi Consumer Healthcare India Ltd.
SANOFICONR.NS stock intraday volume spike summary
Intraday action shows a clear volume-led move. The stock traded INR 4,595.00 at the time of the spike, up INR 585.80 or 14.61%. Volume was 167,833 against an average 3,684, producing a relVolume 310.80 figure. The day range was INR 4,522.50–4,786.00. This pattern signals institutional or block flows, not a routine retail push.
Price, valuation and fundamentals for SANOFICONR.NS stock
Sanofi Consumer Healthcare India (NSE) trades at PE 48.24 with EPS INR 94.62 and a market cap near INR 105,120,971,057.00. Price averages show 50-day INR 4,315.08 and 200-day INR 4,815.04. The stock’s PB ratio 40.91 and P/S 13.01 mark it as richly priced versus healthcare peers. Current margins remain robust with a net profit margin 26.96% and ROE 82.23%.
Technical read and intraday levels for SANOFICONR.NS stock
Momentum indicators are mixed after the volume event. RSI sits at 37.42, suggesting short-term weakness despite the price spike. MACD is negative, with a histogram at -14.87, and ATR is 127.66 indicating wider intraday swings. Key intraday support is INR 4,522.50 and immediate resistance is INR 4,786.00. A conservative short-term target is the quarterly forecast near INR 4,644.77. For traders, a stop below INR 4,522.50 limits downside risk.
Meyka AI grade and model outlook for SANOFICONR.NS stock
Meyka AI rates SANOFICONR.NS with a score out of 100: 69.38 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a quarterly price of INR 4,644.77, which implies a 1.08% upside versus the current INR 4,595.00. Forecasts are model-based projections and not guarantees. Meyka AI, our AI-powered market analysis platform, highlights valuation risk versus peer averages.
Catalysts, news drivers and sector context for SANOFICONR.NS stock
Primary catalysts include brand seasonality, trade stocking, and institutional flows into consumer healthcare. The company sells Allegra, Combiflam and Avil in India and benefits from stable OTC demand. Healthcare sector average PE is 40.48, placing SANOFICONR.NS above peers on valuation. Check corporate disclosures and trading desk notices for block trades. Company information is available on the Sanofi consumer site source and live quotes on the NSE platform source.
Trading strategy on the volume spike for SANOFICONR.NS stock
Volume spike strategies should focus on confirmation and risk control. If price sustains above INR 4,786.00 on follow-through volume, short-term traders can target INR 5,894.50 (year high) with a tight trail. If price fails to hold INR 4,522.50, consider reducing exposure. Use position sizing and set stops given the high ATR 127.66. For more chart context see Meyka’s stock page for SANOFICONR.NS (internal) source.
Final Thoughts
The 27 Feb 2026 intraday volume spike in SANOFICONR.NS stock drove a 14.61% move to INR 4,595.00, backed by 167,833 shares traded. Valuation remains rich with PE 48.24 and PB 40.91, so gains on heavy volume merit caution. Technicals show a mixed signal: RSI 37.42 and negative MACD, yet the volume confirms strong participation. Meyka AI’s model projects a near-term figure at INR 4,644.77, an implied 1.08% upside from INR 4,595.00; remember forecasts are model-based projections and not guarantees. Traders should watch intraday support INR 4,522.50 and resistance INR 4,786.00, manage stops given ATR 127.66, and treat this move as an opportunity to assess position size rather than a conviction buy. Sector context and upcoming earnings on 01 May 2026 remain important catalysts for the NSE-listed Sanofi Consumer Healthcare India Ltd.
FAQs
What caused the SANOFICONR.NS stock volume spike today?
The spike came from a large intraday flow; volume hit 167,833 versus an average 3,684. Traders cited block buying and inventory stocking in consumer healthcare as likely drivers.
What are key support and resistance levels for SANOFICONR.NS stock intraday?
Immediate support is INR 4,522.50 and resistance sits at INR 4,786.00. Watch for sustained volume above resistance for further upside confirmation or failure below support for downside risk.
How does Meyka AI rate SANOFICONR.NS stock and what is the forecast?
Meyka AI rates SANOFICONR.NS with a score out of 100: 69.38 | Grade B | Suggestion: HOLD. The model projects a quarterly price near INR 4,644.77; forecasts are model-based and not guarantees.
Is SANOFICONR.NS stock overvalued by metrics today?
Valuation metrics show a high PE of 48.24 and PB 40.91 versus healthcare peers. That implies premium pricing despite strong margins, so valuation risk exists for new buyers.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.